Orion Oyj logo

Orion Oyj (0M2N)

Market Open
12 Jun, 15:30
LSE LSE
68. 90
-0.1
-0.1449%
- Market Cap
34.42 P/E Ratio
1.74% Div Yield
304 Volume
0 Eps
69
Previous Close
Add Transaction
Day Range
68.9 69.6
Year Range
56.5 75
Want to track 0M2N and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

0M2N trading today lower at €68.9, a decrease of -0.1449% from yesterday's close, completing a monthly decrease of -1.7118% or -€1.2. Over the past 12 months, 0M2N stock gained 8.3333%.
0M2N pays dividends to its shareholders, with the most recent payment made on Oct 23, 2025. The next estimated payment will be in 1 month ago on Apr 23, 2026 for a total of €0.82.
The last earnings report, released on Apr 23, 2026, missed the consensus estimates by -0.729%. On average, the company has fell short of earnings expectations by -0.0156%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on XHEL (EUR).

0M2N Chart

Orion Oyj (0M2N) FAQ

What is the stock price today?

The current price is €68.90.

On which exchange is it traded?

Orion Oyj is listed on LSE.

What is its stock symbol?

The ticker symbol is 0M2N.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 1.74%.

What is its market cap?

As of today, no market cap data is available.

Has Orion Oyj ever had a stock split?

No, there has never been a stock split.

Orion Oyj Profile

Pharmaceuticals Industry
Healthcare Sector
Liisa Hurme CEO
LSE Exchange
FI0009014369 ISIN
FI Country
3,943 Employees
25 Mar 2026 Last Dividend
- Last Split
- IPO Date

Overview

Orion Oyj is a distinguished entity in the global healthcare sector, engrossed in the development, manufacturing, and marketing of pharmaceuticals for both human and veterinary use, in addition to active pharmaceutical ingredients (APIs). With its foundations laid in 1917, the company has established a strong presence not only in its native land of Finland and the broader Scandinavian region but also across Europe, North America, and several other international markets. Aside from its expertise in prescription medications and self-care products, Orion Oyj's operations also span across providing APIs for generic compounds, proprietary products, and extensive contract manufacturing services. Its strategic partnerships, such as with Propeller Health and Amneal Pharmaceuticals, Inc., further signify its collaborative approach towards innovation and expansion in the pharmaceutical domain.

Products and Services

  • Prescription Drugs and Self-care Products

    Orion Oyj offers an extensive portfolio of prescription drugs including Nubeqa for prostate cancer; Precedex, Dexdor, and Precedex for human sedation; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer, and many others. The company also has a focus on treatments for Parkinson's disease through products like Stalevo, Entacapone, and Comtess/Comtan, in addition to Biosimilars for rheumatoid arthritis and inflammatory bowel diseases. Its contribution to heart failure treatment is marked by Simdax for acute decompensated heart failure and Fareston for breast cancer.

  • Easyhaler Products for Respiratory Conditions

    The Easyhaler product line is targeted at patients suffering from asthma and chronic obstructive pulmonary disease, including Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler. These products are part of Orion Oyj's commitment to improving the quality of life for individuals with respiratory conditions.

  • Veterinary Pharmaceuticals

    In the veterinary drug market, Orion Oyj has developed and marketed products like Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie. These products cater to the sedation, analgesia, and anesthesia needs of animals, alongside addressing specific conditions and improving animal health.

  • Active Pharmaceutical Ingredients (APIs)

    Orion Oyj is instrumental in supplying APIs for a broad range of generic compounds and proprietary products. The company also extends its capabilities to offer contract manufacturing services, thereby providing comprehensive solutions from drug development to market.

  • Partnerships and Collaborations

    The company has embraced strategic partnerships to enhance its product offerings and expand its market reach. Notably, its partnership with Propeller Health aims to integrate digital health tools with the Easyhaler® product portfolio, enhancing patient engagement and treatment adherence. Moreover, the research collaboration and license agreement with Amneal Pharmaceuticals, Inc., facilitate the commercialization of Amneal's generic products, exemplifying Orion Oyj's commitment to fostering innovation through partnerships.

Contact Information

Address: Orionintie 1A
Phone: 358 10 4261